The ovarian cancer diagnostics market size has grown strongly in recent years. It will grow from $2.9 billion in 2025 to $3.11 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing incidence of ovarian cancer, growing awareness of women’s health issues, expansion of diagnostic laboratory infrastructure, rising use of imaging and biopsy procedures, availability of cancer screening programs.
The ovarian cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing investments in precision oncology, rising demand for early-stage cancer detection, expansion of ai-driven diagnostic platforms, growing focus on personalized treatment planning, increasing research funding for women’s cancers. Major trends in the forecast period include increasing adoption of biomarker-based diagnostic tests, rising use of advanced imaging modalities, growing integration of ai in cancer detection, expansion of early screening programs, enhanced focus on personalized oncology diagnostics.
The rise in gynecological cancer cases is expected to further accelerate the growth of the ovarian cancer diagnostics market. Gynecologic cancer encompasses any cancer that begins in a woman's reproductive organs. Ovarian cancer diagnostics are essential for treating and managing the disease, preventing recurrence, and enhancing patient outcomes through various therapies. For instance, in October 2025, according to Cancer Australia, an Australia-based government agency, approximately 6,963 new cases of gynecological cancer were diagnosed in Australia in 2024. Consequently, the high prevalence of gynecological cancer is propelling the growth of the ovarian cancer diagnostics market.
Major companies operating in the ovarian cancer diagnostics market are forming strategic partnerships to develop new products and strengthen their market positions. Such collaborations enhance research, development, and commercialization by combining complementary expertise, resources, and geographic reach. For instance, in August 2023, ImmunoGen Inc., a US-based biotechnology company, partnered with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. Under the agreement, ImmunoGen receives upfront and milestone payments along with double-digit royalties, while Takeda obtains exclusive rights to develop and commercialize ELAHERE in Japan. The partnership supports the introduction of this biomarker-directed antibody-drug conjugate for patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer, addressing an unmet clinical need and reinforcing both companies’ commitment to advancing ovarian cancer care.
In May 2025, Sonrai, a UK-based artificial intelligence and data analytics company, entered into a strategic partnership with AOA Dx to leverage AI and multi-omics for early ovarian cancer detection. Through this collaboration, the companies aim to accelerate the development and clinical validation of AOA Dx’s serum-based multi-omic liquid biopsy test, with the goal of enabling earlier diagnosis and improving patient outcomes. AOA Dx is a US-based biotechnology company specializing in non-invasive diagnostic solutions for ovarian cancer.
Major companies operating in the ovarian cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc.
North America was the largest region in the ovarian cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ovarian cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the ovarian cancer diagnostics market by increasing costs of imported diagnostic instruments, reagents, antibodies, imaging components, and laboratory consumables. Diagnostic laboratories and cancer centers in North America and Europe are most affected due to reliance on imported testing equipment, while Asia-Pacific faces higher costs for reagent sourcing. These tariffs are increasing diagnostic test pricing and influencing procurement decisions. However, they are also encouraging domestic reagent production, regional diagnostic manufacturing, and innovation in cost-efficient and locally sourced cancer diagnostic solutions.
The ovarian cancer diagnostics market research report is one of a series of new reports that provides ovarian cancer diagnostics market statistics, including ovarian cancer diagnostics industry global market size, regional shares, competitors with a ovarian cancer diagnostics market share, detailed ovarian cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer diagnostics industry. This ovarian cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Ovarian cancer diagnostics encompass a range of methods and procedures aimed at detecting and diagnosing ovarian cancer. This involves the evaluation of symptoms, physical examinations, and the application of various diagnostic tests. Ovarian cancer, a malignancy affecting the ovaries within the female reproductive system, necessitates accurate diagnostic approaches for timely and effective intervention.
The primary categories of ovarian cancer diagnostic products comprise instruments, kits, and reagents. Instruments play a pivotal role in medical diagnostics, encompassing imaging devices such as ultrasound and MRI, blood tests utilizing markers such as CA-125 and HE4, as well as tissue sampling techniques including biopsy and laparoscopy. Various diagnostic methods, such as biopsy, blood tests, imaging, and others, are deployed to identify specific types of ovarian cancer, including epithelial tumors, germ cell tumors, stromal cell tumors, among others. These diagnostic tools find application across diverse end-users, including cancer diagnostic centers, hospital laboratories, and research institutes. The comprehensive array of diagnostic techniques contributes to accurate and targeted identification of ovarian cancer subtypes, facilitating tailored treatment approaches.
The ovarian cancer diagnostic market includes revenues earned by entities by providing genetic testing, surgery, chemotherapy, target therapy, and hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer diagnostic market also includes sales of ultrasound machines, biopsy tools, genetic testing kits, immunohistochemistry (IHC) kits, and ovarian cancer biomarker panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The ovarian cancer diagnostics market size is expected to see strong growth in the next few years. It will grow to $4.2 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to increasing investments in precision oncology, rising demand for early-stage cancer detection, expansion of ai-driven diagnostic platforms, growing focus on personalized treatment planning, increasing research funding for women’s cancers. Major trends in the forecast period include increasing adoption of biomarker-based diagnostic tests, rising use of advanced imaging modalities, growing integration of ai in cancer detection, expansion of early screening programs, enhanced focus on personalized oncology diagnostics.
The rise in gynecological cancer cases is expected to further accelerate the growth of the ovarian cancer diagnostics market. Gynecologic cancer encompasses any cancer that begins in a woman's reproductive organs. Ovarian cancer diagnostics are essential for treating and managing the disease, preventing recurrence, and enhancing patient outcomes through various therapies. For instance, in October 2025, according to Cancer Australia, an Australia-based government agency, approximately 6,963 new cases of gynecological cancer were diagnosed in Australia in 2024. Consequently, the high prevalence of gynecological cancer is propelling the growth of the ovarian cancer diagnostics market.
Major companies operating in the ovarian cancer diagnostics market are forming strategic partnerships to develop new products and strengthen their market positions. Such collaborations enhance research, development, and commercialization by combining complementary expertise, resources, and geographic reach. For instance, in August 2023, ImmunoGen Inc., a US-based biotechnology company, partnered with Takeda Pharmaceutical Company Limited, a Japan-based pharmaceutical company, to develop and commercialize ELAHERE (mirvetuximab soravtansine-gynx) in Japan. Under the agreement, ImmunoGen receives upfront and milestone payments along with double-digit royalties, while Takeda obtains exclusive rights to develop and commercialize ELAHERE in Japan. The partnership supports the introduction of this biomarker-directed antibody-drug conjugate for patients with folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer, addressing an unmet clinical need and reinforcing both companies’ commitment to advancing ovarian cancer care.
In May 2025, Sonrai, a UK-based artificial intelligence and data analytics company, entered into a strategic partnership with AOA Dx to leverage AI and multi-omics for early ovarian cancer detection. Through this collaboration, the companies aim to accelerate the development and clinical validation of AOA Dx’s serum-based multi-omic liquid biopsy test, with the goal of enabling earlier diagnosis and improving patient outcomes. AOA Dx is a US-based biotechnology company specializing in non-invasive diagnostic solutions for ovarian cancer.
Major companies operating in the ovarian cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, GE HealthCare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Sysmex Corporation, Bio-rad Laboratories Inc., Qiagen N.V., Natera Inc., Myriad Genetics Inc., Invitae Corporation, Guardant Health, Luminex Corporation, NanoString Technologies Inc., Siemens Healthcare Private Limited, Menarini Silicon Biosystems S.p.A., Precipio Inc., Angle plc.
North America was the largest region in the ovarian cancer diagnostics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ovarian cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ovarian cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the ovarian cancer diagnostics market by increasing costs of imported diagnostic instruments, reagents, antibodies, imaging components, and laboratory consumables. Diagnostic laboratories and cancer centers in North America and Europe are most affected due to reliance on imported testing equipment, while Asia-Pacific faces higher costs for reagent sourcing. These tariffs are increasing diagnostic test pricing and influencing procurement decisions. However, they are also encouraging domestic reagent production, regional diagnostic manufacturing, and innovation in cost-efficient and locally sourced cancer diagnostic solutions.
The ovarian cancer diagnostics market research report is one of a series of new reports that provides ovarian cancer diagnostics market statistics, including ovarian cancer diagnostics industry global market size, regional shares, competitors with a ovarian cancer diagnostics market share, detailed ovarian cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer diagnostics industry. This ovarian cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Ovarian cancer diagnostics encompass a range of methods and procedures aimed at detecting and diagnosing ovarian cancer. This involves the evaluation of symptoms, physical examinations, and the application of various diagnostic tests. Ovarian cancer, a malignancy affecting the ovaries within the female reproductive system, necessitates accurate diagnostic approaches for timely and effective intervention.
The primary categories of ovarian cancer diagnostic products comprise instruments, kits, and reagents. Instruments play a pivotal role in medical diagnostics, encompassing imaging devices such as ultrasound and MRI, blood tests utilizing markers such as CA-125 and HE4, as well as tissue sampling techniques including biopsy and laparoscopy. Various diagnostic methods, such as biopsy, blood tests, imaging, and others, are deployed to identify specific types of ovarian cancer, including epithelial tumors, germ cell tumors, stromal cell tumors, among others. These diagnostic tools find application across diverse end-users, including cancer diagnostic centers, hospital laboratories, and research institutes. The comprehensive array of diagnostic techniques contributes to accurate and targeted identification of ovarian cancer subtypes, facilitating tailored treatment approaches.
The ovarian cancer diagnostic market includes revenues earned by entities by providing genetic testing, surgery, chemotherapy, target therapy, and hormone therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The ovarian cancer diagnostic market also includes sales of ultrasound machines, biopsy tools, genetic testing kits, immunohistochemistry (IHC) kits, and ovarian cancer biomarker panels. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Ovarian Cancer Diagnostics Market Characteristics
3. Ovarian Cancer Diagnostics Market Supply Chain Analysis
4. Global Ovarian Cancer Diagnostics Market Trends and Strategies
5. Ovarian Cancer Diagnostics Market Analysis of End Use Industries
7. Global Ovarian Cancer Diagnostics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Ovarian Cancer Diagnostics Total Addressable Market (TAM) Analysis for the Market
9. Ovarian Cancer Diagnostics Market Segmentation
10. Ovarian Cancer Diagnostics Market Regional and Country Analysis
11. Asia-Pacific Ovarian Cancer Diagnostics Market
12. China Ovarian Cancer Diagnostics Market
13. India Ovarian Cancer Diagnostics Market
14. Japan Ovarian Cancer Diagnostics Market
15. Australia Ovarian Cancer Diagnostics Market
16. Indonesia Ovarian Cancer Diagnostics Market
17. South Korea Ovarian Cancer Diagnostics Market
18. Taiwan Ovarian Cancer Diagnostics Market
19. South East Asia Ovarian Cancer Diagnostics Market
20. Western Europe Ovarian Cancer Diagnostics Market
21. UK Ovarian Cancer Diagnostics Market
22. Germany Ovarian Cancer Diagnostics Market
23. France Ovarian Cancer Diagnostics Market
24. Italy Ovarian Cancer Diagnostics Market
25. Spain Ovarian Cancer Diagnostics Market
26. Eastern Europe Ovarian Cancer Diagnostics Market
27. Russia Ovarian Cancer Diagnostics Market
28. North America Ovarian Cancer Diagnostics Market
29. USA Ovarian Cancer Diagnostics Market
30. Canada Ovarian Cancer Diagnostics Market
31. South America Ovarian Cancer Diagnostics Market
32. Brazil Ovarian Cancer Diagnostics Market
33. Middle East Ovarian Cancer Diagnostics Market
34. Africa Ovarian Cancer Diagnostics Market
36. Ovarian Cancer Diagnostics Market Competitive Landscape and Company Profiles
37. Ovarian Cancer Diagnostics Market Other Major and Innovative Companies
40. Ovarian Cancer Diagnostics Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Ovarian Cancer Diagnostics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses ovarian cancer diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for ovarian cancer diagnostics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ovarian cancer diagnostics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Instruments; Kits; Reagents2) By Diagnosis Type: Biopsy; Blood Test; Imaging; Other Diagnosis Types
3) By Cancer Type: Epithelial Tumor; Germ Cell Tumor; Stromal Cell Tumor
4) By End User: Cancer Diagnostic Centers; Hospital Laboratories
Subsegments:
1) By Instruments: Imaging Systems; Biopsy Devices; Molecular Diagnostic Instruments2) By Kits: Diagnostic Test Kits; Screening Kits
3) By Reagents: Antibodies; Enzymes; Assay Reagents
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; AstraZeneca plc; Abbott Laboratories; GlaxoSmithKline plc; Eli Lilly and Company; GE HealthCare Technologies Inc.; Quest Diagnostics Incorporated; Agilent Technologies Inc.; Hologic Inc.; Illumina Inc.; PerkinElmer Inc.; Sysmex Corporation; Bio-rad Laboratories Inc.; Qiagen N.V.; Natera Inc.; Myriad Genetics Inc.; Invitae Corporation; Guardant Health; Luminex Corporation; NanoString Technologies Inc.; Siemens Healthcare Private Limited; Menarini Silicon Biosystems S.p.A.; Precipio Inc.; Angle plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Ovarian Cancer Diagnostics market report include:- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- AstraZeneca plc
- Abbott Laboratories
- GlaxoSmithKline plc
- Eli Lilly and Company
- GE HealthCare Technologies Inc.
- Quest Diagnostics Incorporated
- Agilent Technologies Inc.
- Hologic Inc.
- Illumina Inc.
- PerkinElmer Inc.
- Sysmex Corporation
- Bio-rad Laboratories Inc.
- Qiagen N.V.
- Natera Inc.
- Myriad Genetics Inc.
- Invitae Corporation
- Guardant Health
- Luminex Corporation
- NanoString Technologies Inc.
- Siemens Healthcare Private Limited
- Menarini Silicon Biosystems S.p.A.
- Precipio Inc.
- Angle plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 3.11 Billion |
| Forecasted Market Value ( USD | $ 4.2 Billion |
| Compound Annual Growth Rate | 7.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 26 |
